Scholarlink

<p>Synaptotagmin 12 (SYT12), a protein found to be upregulated in papillary thyroid cancer (PTC), has emerged as a potential biomarker for this malignancy. However, the mechanisms governing its expression remain poorly understood. In this study, we identify SYT12 as a novel substrate of SPOP, an adaptor of the Cullin 3 E3 ubiquitin ligase complex. SPOP binds to SYT12 and mediates SYT12’s K48-linked polyubiquitination and subsequent proteasomal degradation. This interaction is dependent on the degron motif within SYT12, and deletion or mutation of the degron significantly impairs SPOP binding and stabilizes SYT12. We further demonstrate that GSK-3β-mediated phosphorylation of the degron is essential for SPOP recognition. Pharmacological inhibition of GSK-3β disrupts the SPOP–SYT12 interaction and increases SYT12 protein levels. Functionally, the SPOP–SYT12 axis modulates PTC cell viability and proliferation. Collectively, these findings uncover a novel regulatory mechanism of SYT12 expression and suggest that targeting the SPOP–SYT12 pathway may represent a promising therapeutic strategy for PTC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SPOP-dependent destabilization of SYT12 in a GSK-3β-dependent manner in papillary thyroid cancer cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月10日

查看全文
  • Shaocheng Zhou,
  • Qidan Du,
  • Limei Xu,
  • Xiaohong Kang

摘要

Synaptotagmin 12 (SYT12), a protein found to be upregulated in papillary thyroid cancer (PTC), has emerged as a potential biomarker for this malignancy. However, the mechanisms governing its expression remain poorly understood. In this study, we identify SYT12 as a novel substrate of SPOP, an adaptor of the Cullin 3 E3 ubiquitin ligase complex. SPOP binds to SYT12 and mediates SYT12’s K48-linked polyubiquitination and subsequent proteasomal degradation. This interaction is dependent on the degron motif within SYT12, and deletion or mutation of the degron significantly impairs SPOP binding and stabilizes SYT12. We further demonstrate that GSK-3β-mediated phosphorylation of the degron is essential for SPOP recognition. Pharmacological inhibition of GSK-3β disrupts the SPOP–SYT12 interaction and increases SYT12 protein levels. Functionally, the SPOP–SYT12 axis modulates PTC cell viability and proliferation. Collectively, these findings uncover a novel regulatory mechanism of SYT12 expression and suggest that targeting the SPOP–SYT12 pathway may represent a promising therapeutic strategy for PTC.